Gyre Therapeutics Statistics
Total Valuation
GYRE has a market cap or net worth of $852.81 million. The enterprise value is $827.74 million.
Important Dates
The last earnings date was Monday, March 17, 2025, after market close.
| Earnings Date | Mar 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GYRE has 93.61 million shares outstanding. The number of shares has increased by 55.39% in one year.
| Current Share Class | 93.61M |
| Shares Outstanding | 93.61M |
| Shares Change (YoY) | +55.39% |
| Shares Change (QoQ) | -16.26% |
| Owned by Insiders (%) | 6.05% |
| Owned by Institutions (%) | 1.95% |
| Float | 23.94M |
Valuation Ratios
The trailing PE ratio is 189.49 and the forward PE ratio is 75.92.
| PE Ratio | 189.49 |
| Forward PE | 75.92 |
| PS Ratio | 7.33 |
| Forward PS | n/a |
| PB Ratio | 12.42 |
| P/TBV Ratio | 13.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 68.49 |
| EV / Sales | 7.83 |
| EV / EBITDA | 46.46 |
| EV / EBIT | 51.00 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.32, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.32 |
| Quick Ratio | 2.64 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.09 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 20.24% and return on invested capital (ROIC) is 11.34%.
| Return on Equity (ROE) | 20.24% |
| Return on Assets (ROA) | 8.38% |
| Return on Invested Capital (ROIC) | 11.34% |
| Return on Capital Employed (ROCE) | 15.33% |
| Revenue Per Employee | $182,655 |
| Profits Per Employee | $20,872 |
| Employee Count | 579 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 0.73 |
Taxes
In the past 12 months, GYRE has paid $5.32 million in taxes.
| Income Tax | 5.32M |
| Effective Tax Rate | 22.91% |
Stock Price Statistics
The stock price has decreased by -48.03% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -48.03% |
| 50-Day Moving Average | 11.14 |
| 200-Day Moving Average | 12.17 |
| Relative Strength Index (RSI) | 40.54 |
| Average Volume (20 Days) | 210,948 |
Short Selling Information
The latest short interest is 1.53 million, so 1.63% of the outstanding shares have been sold short.
| Short Interest | 1.53M |
| Short Previous Month | 1.35M |
| Short % of Shares Out | 1.63% |
| Short % of Float | 6.38% |
| Short Ratio (days to cover) | 17.59 |
Income Statement
In the last 12 months, GYRE had revenue of $105.76 million and earned $12.09 million in profits. Earnings per share was $0.05.
| Revenue | 105.76M |
| Gross Profit | 101.87M |
| Operating Income | 16.23M |
| Pretax Income | -74.61M |
| Net Income | 12.09M |
| EBITDA | 17.82M |
| EBIT | 16.23M |
| Earnings Per Share (EPS) | $0.05 |
Full Income StatementBalance Sheet
The company has $26.67 million in cash and $1.60 million in debt, giving a net cash position of $25.07 million or $0.27 per share.
| Cash & Cash Equivalents | 26.67M |
| Total Debt | 1.60M |
| Net Cash | 25.07M |
| Net Cash Per Share | $0.27 |
| Equity (Book Value) | 98.40M |
| Book Value Per Share | 0.73 |
| Working Capital | 45.27M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$3.64 million and capital expenditures -$2.32 million, giving a free cash flow of -$5.96 million.
| Operating Cash Flow | -3.64M |
| Capital Expenditures | -2.32M |
| Free Cash Flow | -5.96M |
| FCF Per Share | -$0.06 |
Full Cash Flow StatementMargins
Gross margin is 96.33%, with operating and profit margins of 15.35% and 11.43%.
| Gross Margin | 96.33% |
| Operating Margin | 15.35% |
| Pretax Margin | 21.95% |
| Profit Margin | 11.43% |
| EBITDA Margin | 16.85% |
| EBIT Margin | 15.35% |
| FCF Margin | n/a |